Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Not available.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.3324/haematol.2025.288003 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Sequential intrathoracic injection and intravenous infusion of BCMA CAR-T cells in a patient with relapsed/refractory primary plasma cell leukemia.
Int J Hematol
September 2025
Bone Marrow Transplantation Center, the First Affiliated Hospital, Zhejiang University School of Medicine, No. 79 Qingchun Road, Hangzhou, 310003, China.
Patients with primary plasma cell leukemia (pPCL), particularly those with extramedullary disease (EMD), face a poor prognosis even with chimeric antigen receptor (CAR)-T cell therapy. This case report describes a patient with relapsed/refractory pPCL and life-threatening malignant pleural effusion (PE) treated with intrapleural CAR-T cells targeting B-cell maturation antigens. CAR-T cell expansion within the PE was observed, along with a rapid reduction in leukemia cell count and PE volume.
View Article and Find Full Text PDFLongitudinal single-cell analysis reveals treatment-resistant stem and mast cells with potential treatments for pediatric AML.
Leukemia
September 2025
Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, Atlanta, GA, USA.
Pediatric acute myeloid leukemia (pAML) is a heterogeneous malignancy driven by diverse cytogenetic mutations. While identification of cytogenetic lesions improved risk stratification, prognostication remains inadequate with 30% of standard-risk patients experiencing relapse within 5 years. To deeply characterize pAML heterogeneity and identify poor outcome-associated blast cell profiles, we performed an analysis on 708,285 cells from 164 bone marrow biopsies of 95 patients and 11 healthy controls.
View Article and Find Full Text PDFImpact of Measurable Residual Disease Status on Outcomes After HLA-Matched Donor Allogeneic Hematopoietic Cell Transplantation in Acute Myeloid Leukemia.
Clin Lymphoma Myeloma Leuk
August 2025
The Mikael Rayaan Foundation Global Transplantation and Cellular Therapy Consortium, Kansas City, KS; Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Medical Center, Kansas City, KS; U.S Myeloma Innovations Research Collaborative, Kansas City, KS. Electronic addres
Background: Allogeneic hematopoietic stem cell transplantation (allo-HCT) is a key treatment for acute myeloid leukemia (AML). Measurable residual disease (MRD) predicts post-transplant outcomes. This study evaluates the impact of pretransplant MRD status on outcomes in AML patients undergoing allo-HCT.
View Article and Find Full Text PDFComparison of autologous and allogeneic hematopoietic stem cell transplantation for primary plasma cell leukemia in Japan.
Transplant Cell Ther
September 2025
Division of Hematology and Clinical Laboratory Medicine, Department of Multidisciplinary Internal Medicine, Faculty of Medicine, Tottori University, Yonago, Japan. Electronic address:
Primary plasma cell leukemia (pPCL) is a rare and aggressive subtype of plasma cell malignancy. Although hematopoietic stem cell transplantation (HCT), including autologous HCT (auto-HCT) and allogeneic HCT (allo-HCT), is widely used, an optimal treatment strategy is undetermined. We retrospectively analyzed patients with pPCL who underwent HCT between 2006 and 2022 in Japan using Japanese registry data.
View Article and Find Full Text PDFPotential role of miR-29b from mesenchymal stromal cell-derived extracellular vesicles in leukemic cell progression.
PLoS One
September 2025
Cancer Research Institute, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.
Crosstalk between leukemic cells and their surrounding mesenchymal stromal cells (MSCs) in the bone marrow microenvironment is crucial for the pathogenesis of myelodysplastic syndromes (MDS) and is mediated by extracellular vesicles (EVs). The EV-specific miRNAs derived from MDS-MSCs remain poorly explored. EVs isolated from HS-5, an immortalized stromal cell line, promoted the proliferation and 5-azacytidine (AZA) resistance of SKM-1 cells.
View Article and Find Full Text PDF